Ocumension Therapeutics (1477.HK)
HKD 5.55
(0.36%)
HKD 5.55
(0.36%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -402.14 Million CNY | -1.24% |
| 2022 | -397.23 Million CNY | -3.12% |
| 2021 | -385.2 Million CNY | 83.05% |
| 2020 | -2.27 Billion CNY | -70.07% |
| 2019 | -1.33 Billion CNY | -2602.23% |
| 2018 | -49.44 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q2 | -112.43 Million CNY | 0.0% |
| 2023 Q4 | -88.63 Million CNY | 0.0% |
| 2023 FY | -402.14 Million CNY | -1.24% |
| 2023 Q1 | -112.43 Million CNY | 5.26% |
| 2023 Q3 | -88.63 Million CNY | 21.16% |
| 2022 Q1 | -109.25 Million CNY | -5.97% |
| 2022 Q2 | -109.25 Million CNY | 0.0% |
| 2022 Q4 | -118.67 Million CNY | 0.0% |
| 2022 Q3 | -118.67 Million CNY | -8.62% |
| 2022 FY | -397.23 Million CNY | -3.12% |
| 2021 Q1 | -89.86 Million CNY | 23.34% |
| 2021 FY | -385.2 Million CNY | 83.05% |
| 2021 Q4 | -103.1 Million CNY | 0.0% |
| 2021 Q3 | -103.1 Million CNY | -14.73% |
| 2021 Q2 | -89.86 Million CNY | 0.0% |
| 2020 Q3 | -117.22 Million CNY | -7.9% |
| 2020 Q2 | -108.63 Million CNY | 0.0% |
| 2020 FY | -2.27 Billion CNY | -70.07% |
| 2020 Q1 | -108.63 Million CNY | -115.05% |
| 2020 Q4 | -117.22 Million CNY | 0.0% |
| 2019 Q3 | -50.51 Million CNY | -74.45% |
| 2019 FY | -1.33 Billion CNY | -2602.23% |
| 2019 Q4 | -50.51 Million CNY | 0.0% |
| 2019 Q1 | -28.95 Million CNY | 0.0% |
| 2019 Q2 | -28.95 Million CNY | 0.0% |
| 2018 FY | -49.44 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 67.76 Million HKD | 693.417% |
| CK Life Sciences Int'l., (Holdings) Inc. | 897.95 Million HKD | 144.785% |